Renal Business Today

Federal Trade Commission (FTC)

FTC Requires Fresenius to Sell 60 Clinics

WASHINGTON—Fresenius Medical Care AG & Co. has gained a rival dialysis provider, Liberty Dialysis Holdings, Inc., but has been requested by The Federal Trade Commission to sell 60 outpatient dialysis clinics in 43 local markets in order to prevent competition in ...More
February 29, 2012
Posted in News, Business, Government & Regulation
Sanofi Aventis Acquires Genzyme for $20.1 Billion

CAMBRIDGE, Mass.—Sanofi-aventis will acquire Genzyme Corp. for $74 per share in cash, or approximately $20.1 billion, according to a Feb. 16 news release. ...More
February 16, 2011
Posted in News, Business, Government & Regulation
FTC to Host Accountable Care Organizations Workshop

On October 5, the Federal Trade Commission will co-host a workshop on several issues associated with Accountable Care Organizations (ACOs). ...More
September 10, 2010
Posted in Blog, Government & Regulation
Genzyme Sues Watson Over Generic Renvela Application

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. said July 12 that it has submitted an application to the U.S. Food and Drug Administration to approve a generic form of Genzyme’s phosphate binder Renvela. ...More
July 13, 2010
Posted in News, Government & Regulation
‘Red Flags’ Rule Now Delayed Until Nov. 1

WASHINGTON—Moving an Aug. 1 deadline, the Federal Trade Commission will wait until Nov. 1 to enforce a provision of the “red flags” rule requiring physicians and hospitals to adopt written plans for tracking and responding to indicators of identity theft in their billing ...More
August 11, 2009
Posted in News, Business, Government & Regulation, Practice Management
FTC Delays Red Flag Rule Enforcement

WASHINGTON—Physician practices now have until Aug. 1, 2009, to comply with the Federal Trade Commission's (FTC) Identity Theft Red Flags Rule. ...More
May 6, 2009
Posted in News, Business, Government & Regulation
Regulators clear Fresenius acquisition of APP Pharma

SCHAUMBURG, Ill.—The U.S. Federal Trade Commission has approved Fresenius’ buyout of APP Pharmaceuticals, which makes the blood-thinning drug heparin used in dialysis treatments. ...More
September 2, 2008
Posted in News, Business, Clinical & Pharma, Government & Regulation